Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. by Hiromi Yamaguchi (2396248)

Subjects:

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…</p> <p>The virus that causes coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a way of weakening the body’s early immune defense, called the innate immune system. …”

Comparison of detection results between YOLOv5s and P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

Subjects:

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

Subjects:

5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

Subjects:

Structure of P-YOLOv5s-GRNF. by Zhongjian Xie (4633099)

Subjects:

Reasons for decreasing fear towards COVID-19. by Misganu Endriyas (5581679)

Comparative experiment of different YOLOv5 versions. by Zhongjian Xie (4633099)

Subjects:

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects: